Length of hospitalisation (days) · exacerbations of COPD
1 finding from 1 review
FEV1 · exacerbations of COPD
1 finding from 1 review
QoL · exacerbations of COPD
1 finding from 1 review
Intervention not reported
Pathogenic bacteria / plaque composition around brackets (fewer pathogenic bacteria with flash-free vs APC; comparable plaque quantity)
1 finding from 1 review
no estimate extracted
1 study
GRADE not reported
AEs · chronic pain (excluding headache) in adults
It is very uncertain whether CBT changes adverse events (number of people with adverse events) (Lower events… compared with TAU (post‐treatment) (very low certainty).
Depressive symptoms · men and women aged over 18 years with chronic fatigue syndrome
1 finding from 1 review
Depression Measured after 52 weeks HADS depression score, 0‐21 points Low score means fewer symptoms · men and women aged over 18 years with chronic fatigue syndrome
1 finding from 1 review
Loss of fewer than 15 letters visual acuity at one year · people with neovascular age‐related macular degeneration
Summary of findings: anti‐VEGF treatment leads to higher loss of fewer than 15 letters visual acuity at 1 year compared with control (high certainty).
1 finding from 1 review
Loss of fewer than 15 letters visual acuity at one year · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in loss of fewer than 15 letters visual acuity at 1 year compared with ranibizumab (high certainty).
1 finding from 1 review
Migraine frequency Number of attacks · adults with migraine
1 finding from 1 review
Symptom score at 10 days. Measured on a 7‐point scale (0 to 6) ; lower score denotes fewer symptoms · acute asthma exacerbation
1 finding from 1 review
Intervention not reported
Pain: 50% reduction in headache frequency Post‐treatment Lower scores = fewer headaches · Children and adolescents with chronic pain
It is very uncertain whether the intervention changes pain: 50% reduction in headache frequency Post‐treatment Lower… (very low certainty).
1 finding from 1 review
Intervention not reported
Sleep onset latency Participant reports. Scale from 30 to 540 minutes; fewer minutes equalled better outcome; CFB and double‐blind average values included · Patients with insomnia
1 finding from 1 review
Intervention not reported
Wake time after sleep onset Participant reports. Scale from: 30 to 540 minutes; fewer minutes equalled better outcome; CFB and double‐blind average values included · Patients with insomnia
1 finding from 1 review
Intervention not reported
Respiratory symptoms (symptoms) Breathlessness, Cough and Sputum Scale Scale from 0 to 12. Lower score indicates fewer symptoms · individuals with stable bronchiectasis
The intervention showed no clear difference in respiratory symptoms (symptoms) Breathlessness, Cough and Sputum… (low certainty).
1 finding from 1 review
Intervention not reported
Asthma symptoms Different scales in different studies (lower scores mean fewer symptoms) · children and adolescents aged 18 years and under studies with asthma
1 finding from 1 review
Intervention not reported
Crash outcomes measured: Killed and seriously injured (KSIs) and personal injury crashes (PICs). Across all sites KSI's decreased by 42%. This equated to about 1700 fewer KSI's per annum at these camera sites. Fixed cameras in both urban (47% redu...
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Outcomes at ≥ 3 months · preventing early recurrence after ischaemic stroke or TIA
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Stroke · preventing early recurrence after ischaemic stroke or TIA
Multiple probably leads to lower stroke compared with fewer antiplatelet agents (moderate certainty).
1 finding from 1 review
Deaths due to vascular events · preventing early recurrence after ischaemic stroke or TIA
Multiple showed no clear difference in vascular death compared with fewer antiplatelet agents (moderate certainty).
1 finding from 1 review